Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

46.24 +0.47 (+1.04%)

Streaming Delayed Price Updated: 1:47 PM EST, Jan 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

40 41 Next >

Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment ↗

May 19, 2025

Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall.

Via Benzinga

SANOFI-ADR (NASDAQ:SNY) – A Reliable Dividend Stock with Strong Fundamentals ↗

May 15, 2025

SANOFI-ADR (SNY) offers a strong 4.27% dividend yield with sustainable payouts, solid profitability, and manageable debt, making it a top pick for income investors.

Via Chartmill

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 ↗

May 14, 2025

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.

Via Benzinga

Bristol-Myers Squibb Strikes $350 Million Deal To End Hawaii's Plavix Lawsuit ↗

May 13, 2025

Bristol-Myers Squibb will pay $350 million to settle Hawaii's lawsuit over Plavix marketing practices, ending claims without admitting wrongdoing and avoiding trial.

Via Benzinga

Topics Lawsuit

Earnings Scheduled For April 24, 2025 ↗

April 24, 2025

Via Benzinga

Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say ↗

May 12, 2025

JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting...

Via Stocktwits

Topics ETFs Government Stocks

S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform ↗

May 12, 2025

It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.

Via Investor's Business Daily

Topics Government Stocks

COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why ↗

May 08, 2025

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year outlook raised above expectations.

Via Benzinga

AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma ↗

May 02, 2025

AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over 5,000 patients.

Via Benzinga

SANOFI-ADR (NASDAQ:SNY): A Strong Growth Stock with Technical Breakout Potential ↗

April 30, 2025

SANOFI-ADR (NASDAQ:SNY): A Strong Growth Stock with Technical Breakout Potential

Via Chartmill

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit ↗

April 24, 2025

Sanofi Q1 2025 revenue rose 10.8% to $10.42 billion, driven by Dupixent and new launches, as earnings climbed 20.1% and 2025 guidance was reaffirmed.

Via Benzinga

Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed ↗

April 24, 2025

Roche rode its pharmaceuticals growth to a sales beat, while Sanofi's report was more complicated.

Via Investor's Business Daily

Topics Earnings Government

Why SANOFI-ADR (NASDAQ:SNY) provides a good dividend, while having solid fundamentals. ↗

April 23, 2025

Why the dividend investor may take a look at SANOFI-ADR (NASDAQ:SNY).

Via Chartmill

Regeneron Expands US Manufacturing With $3 Billion Fujifilm Deal ↗

April 22, 2025

Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and long-term production.

Via Benzinga

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

April 18, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study ↗

April 15, 2025

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

Via Benzinga

How Do Investors Really Feel About Sanofi? ↗

April 10, 2025

Via Benzinga

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗

April 09, 2025

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Via Benzinga

Topics Government Supply Chain World Trade

Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports ↗

April 09, 2025

Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.

Via Investor's Business Daily

Topics Government Stocks World Trade

All the Stocks Warren Buffett Bought in the Last 2 Recessions: Are They Smart Picks Now? ↗

April 06, 2025

Via The Motley Fool

Topics Economy Government World Trade

Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst ↗

April 03, 2025

Biotech stocks face a tough 2025 with SMid-cap losses up to 40% YTD. BofA cites FDA changes, tariffs, and capital struggles but notes potential opportunities.

Via Benzinga

Topics World Trade

Why Is French Pharma Giant Sanofi Stock Trading Higher On Thursday? ↗

April 03, 2025

Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response rates and reduced disease flares.

Via Benzinga

Lamb Weston Posts Better-Than-Expected Results, Joins Sanofi And Other Big Stocks Moving Higher On Thursday ↗

April 03, 2025

Via Benzinga

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? ↗

March 31, 2025

The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9.

Via Investor's Business Daily

FDA Approves Sanofi's Hemophilia Drug ↗

March 31, 2025

FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with as few as six injections per year.

Via Benzinga

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

March 28, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Don't overlook SANOFI-ADR (NASDAQ:SNY)—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

March 26, 2025

Discover SANOFI-ADR, an undervalued stock. NASDAQ:SNY showcases solid financial health and profitability while maintaining an appealing valuation.

Via Chartmill

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

This ACNB Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday ↗

March 21, 2025

Via Benzinga

Sanofi Strengthens Its Immune System-Focused Pipeline With Around $2 Billion Dren Bio Deal ↗

March 20, 2025

Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with a promising bispecific antibody.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

40 41 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.